PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 47/36, 47/38, 47/40, 47/44, 9/12, 9/14, 9/72

A1

(11) International Publication Number: **WO 00/15262**

(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/US99/21109

(22) International Filing Date: 13 September 1999 (13.09.99)

(30) Priority Data:
60/100,163 14 September 1998 (14.09.98) US

(71) Applicant *(for all designated States except US)*: INHALE THERAPEUTIC SYSTEMS, INC. [US/US]; 150 Industrial Road, San Carlos, CA 94070 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CLARK, Andrew [GB/US]; 436 Valdez Avenue, Half Moon Bay, CA 94019 (US). KUO, Mei-Chang [US/US]; 1823 Middlefield Road, Palo Alto, CA 94301 (US). LALOR, Cecily [US/US]; 1337 Orange Avenue, San Carlos, CA 94070 (US).

(74) Agents: EVANS, Suzan, T. et al.; Inhale Therapeutic Systems, Inc., 150 Industrial Road, San Carlos, CA 94070 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DRY POWDER ACTIVE AGENT PULMONARY DELIVERY

(57) Abstract

The present invention is directed to particulate compositions and methods for delivering an active agent to the lung of a human patient. The active agent formulation is in dry powder form and exhibits (i) low moisture sorption, and (ii) a resistance to hygrosscopic growth, particularly under simulated lung conditions.